FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics
PHOENIX, Dec. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that its New Drug Application (NDA) for a novel formulation of buprenorphine as a sublingual spray for the management of moderate- …